Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Feb 21;121(8):1296-303.
doi: 10.1182/blood-2012-06-439307. Epub 2013 Jan 3.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M Ghobrial  1 , Federico Campigotto, Timothy J Murphy, Erica N Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott Rodig, Kenneth C Anderson, Paul G Richardson, Edie Weller, Jeffrey Matous
Affiliations
Clinical Trial

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

Irene M Ghobrial et al. Blood. .

Abstract

The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients received panobinostat at 30 mg 3 times a week; 12 of 36 (33%) patients were enrolled at 25 mg dose. A total of 36 patients received therapy. The median age was 62 years (range, 47-80) and the median number of prior therapies was 3 (range, 1-8). All of the patients had received prior rituximab. Minimal response (MR) or better was achieved in 47% of patients (90% confidence interval [CI], 33-62), with 22% partial remissions and 25% MR. In addition, 18 (50%) patients achieved stable disease and none showed progression while on therapy. The median time to first response was 1.8 months (range, 1.7-3.2). The median progression-free survival was 6.6 months(90% CI, 5.5-14.8). Grade 3 and 4 toxicities included thrombocytopenia (67%), neutropenia (36%), anemia (28%), leukopenia (22%), and fatigue (11%). We conclude that panobinostat is an active therapeutic agent in patients with relapsed/ refractory WM. This study (www.clinicaltrials.gov identifier: NCT00936611) establishes a role for histone deacetylase inhibitors as an active class of therapeutic agents in WM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram of the study design.
Figure 2
Figure 2
Waterfall of the maximum difference in IgM from baseline throughout the study (including follow-up; N = 36).
Figure 3
Figure 3
Duration of response, progression-free, and event-free survival in patients treated with panobinostat. (A) Kaplan-Meier estimation of the duration of response (MR or better) end point (n = 17). (B) Kaplan-Meier estimation of the PFS end point (n = 36): PFS was similar to TTP. (C) Kaplan-Meier estimation of the EFS end point (n = 36).
Figure 4
Figure 4
Correlative studies on samples obtained from patients treated with panobinostat. (A) Immunohistochemistry for CD20 and percentage BM involvement in pre- and posttreatment samples. (B) ELISA for acetylated histone 3 (H3) in PBMCs of samples before therapy in 10 patients with the clinical responses that were obtained in these patients. (C) ELISA for acetylated H3 in PBMCs of samples before and after therapy in 3 patients. Although the levels before and after therapy were not statistically different, there was a trend of increases in the level of acetylated H3 after therapy that is consistent with the activity of HDAC inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–226. - PubMed
    1. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol. 2004;5(3):239–247. - PMC - PubMed
    1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23(7):1564–1577. - PubMed
    1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. - PubMed
    1. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4(11):679–685. - PubMed

Publication types

MeSH terms

Associated data